Join Growin Stock Community!

Revolution medicines, inc.RVMD.US Overview

US StockHealthcare
(No presentation for RVMD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RVMD AI Insights

RVMD Overall Performance

RVMD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RVMD Recent Performance

-0.76%

Revolution medicines, inc.

0.05%

Avg of Sector

-0.31%

S&P500

RVMD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RVMD Key Information

RVMD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RVMD Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Price of RVMD

RVMD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RVMD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.85
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9035.10
PB Ratio
12.35
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.85
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9035.10
PB Ratio
12.35
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is RVMD's latest earnings report released?

    The most recent financial report for Revolution medicines, inc. (RVMD) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RVMD's short-term business performance and financial health. For the latest updates on RVMD's earnings releases, visit this page regularly.

  • How much debt does RVMD have?

    As of the end of the reporting period, Revolution medicines, inc. (RVMD) had total debt of 427.15M, with a debt ratio of 0.18. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RVMD have?

    At the end of the period, Revolution medicines, inc. (RVMD) held Total Cash and Cash Equivalents of 388.6M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RVMD's EPS continuing to grow?

    According to the past four quarterly reports, Revolution medicines, inc. (RVMD)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.89. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RVMD?

    Revolution medicines, inc. (RVMD)'s Free Cash Flow (FCF) for the period is -276.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 97.95% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of RVMD?

    The latest valuation data shows Revolution medicines, inc. (RVMD) has a Price-To-Earnings (PE) ratio of -18.09 and a Price/Earnings-To-Growth (PEG) ratio of -0.58. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.